Seattle Genetics to Present at Upcoming Investor Conferences

Cowen Health Care Conference 2015
Barclay’s Global Healthcare Conference 2015

BOTHELL, Wash.--()--Seattle Genetics, Inc. (NASDAQ:SGEN) announced today that management will present at the following upcoming investor conferences. The presentations will be webcast live and available for replay from Seattle Genetics’ website at www.seattlegenetics.com in the Investors and News section.

Cowen and Company 35th Annual Health Care Conference

Tuesday, March 3, 8:40 a.m. Eastern Time, Boston

Barclays Global Healthcare Conference

Wednesday, March 11, 8:30 a.m. Eastern Time, Miami

About Seattle Genetics

Seattle Genetics is a biotechnology company focused on the development and commercialization of innovative antibody-based therapies for the treatment of cancer. Seattle Genetics is leading the field in developing antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. The company’s lead product, ADCETRIS® (brentuximab vedotin) is an ADC that, in collaboration with Takeda Pharmaceutical Company Limited, has been approved for two indications in 50 countries, including the U.S., Canada, Japan and members of the European Union. Additionally, ADCETRIS is being evaluated broadly in more than 30 ongoing clinical trials. Seattle Genetics is also advancing a robust pipeline of clinical-stage programs, including SGN-CD19A, SGN-CD33A, SGN-LIV1A, ASG-22ME, ASG-15ME and SEA-CD40. Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including AbbVie, Agensys (an affiliate of Astellas), Bayer, Genentech, GlaxoSmithKline and Pfizer. More information can be found at www.seattlegenetics.com.

Contacts

Seattle Genetics, Inc.
Peggy Pinkston, 425-527-4160
ppinkston@seagen.com

Contacts

Seattle Genetics, Inc.
Peggy Pinkston, 425-527-4160
ppinkston@seagen.com